Studying immune markers for CMV in pregnancy
Part of Genetic & congenital, Infections, Women’s health & pregnancy clinical trials.
This study looks at how the immune system responds to a first-time cytomegalovirus (CMV) infection during pregnancy. The goal is to find better ways to predict if the virus will pass to the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and pregnant.
- You had your first CMV infection while pregnant, and it started before week 26 of pregnancy.
- The infection began within the last 3 months.
- You do not have hepatitis B, hepatitis C, or HIV.
- You do not have a known immune system problem or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for biological markers in the mother's blood that might predict how exposure to inflammation during pregnancy could change a baby's brain development. The goal is to understand these effects in healthy pregnancies and those with certain inflammatory conditions.
This trial is testing a computer program that helps doctors interpret blood test results for CMV infection in pregnant women. If you are pregnant and have had a CMV blood test, this study may help doctors better understand your results.
This is an observational study that looks at how babies with congenital CMV infection are diagnosed and managed in real life. It may help doctors understand which care approaches are used and how they relate to outcomes over time.
This research study examines blood samples from newborns to identify biological markers (proteins and genetic signals) that could help detect and understand congenital cytomegalovirus (CMV) infection—a virus some babies are born with. Finding these markers might help doctors identify infected infants earlier and develop better treatments.
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
This Phase 2 trial tests an immune treatment made from donor T-cells to help the body fight congenital CMV infection in newborns. It may be an option if your baby is very young, has evidence of CMV infection, and meets specific blood, kidney, and liver safety limits.
Hear when a new Human Cytomegalovirus (HCMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.